CMV

COMMUNIQUÉS West-GlobeNewswire

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
06/08/2025
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of [...]
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
06/08/2025
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY ® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth [...]
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
06/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class [...]
electroCore Announces Second Quarter 2025 Financial Results
06/08/2025
Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, [...]
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
06/08/2025
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 [...]
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
06/08/2025
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% Yo Y, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% [...]
Certara Reports Second Quarter 2025 Financial Results
06/08/2025
Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
06/08/2025
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE [...]
DLH Reports Fiscal 2025 Third Quarter Results
06/08/2025
Robust Q3 Cash Flow Fuels Accelerated Debt Reduction; Strong Management of Operating Expenses Assures Margin Delivery ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company [...]
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
06/08/2025
Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 million Second Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, [...]
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
06/08/2025
Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trial Enrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through [...]
STERIS Announces Financial Results for Fiscal 2026 First Quarter
06/08/2025
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34 Fiscal 2026 revenue and [...]
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
06/08/2025
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™ -1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN- [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
06/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
06/08/2025
Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs) in some of the most [...]
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
06/08/2025
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small [...]
STERIS Announces Chief Financial Officer Transition
06/08/2025
Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton, Chief Accounting Officer DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that [...]
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
06/08/2025
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/08/2025
MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]

Pages